Evidence-based mini-review: the role of alkylating agents in the initial treatment of chronic lymphocytic leukemia patients with the 11q deletion.

Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program

Volumn 2010, Issue , 2010, Pages 90-92

  Ding, Wei ^a   Ferrajoli, Alessandra ^b  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT;

CHROMOSOME 11; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; EVIDENCE BASED MEDICINE; GENETICS; HUMAN; IMMUNOTHERAPY; REVIEW;

ALKYLATING AGENTS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 11; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOTHERAPY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;

EID: 79955007785     PISSN: None     EISSN: 15204383     Source Type: Journal    
DOI: 10.1182/asheducation-2010.1.90     Document Type: Review

References (0)